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Objectives: In hilar cholangiocarcinoma, resection provides the only opportunity for longterm survival.
A US experience of hilar cholangiocarcinoma was examined to determine the effect of clinical experience
on negative margin (R0) resection rates.
Methods: We conducted a retrospective analysis of 110 consecutive hilar cholangiocarcinoma patients
presenting over an 18-year period. Analyses were performed using chi-squared, Wilcoxon rank sum and
Kaplan–Meier methods, and multivariable Cox and logistic regression modelling.
Results: Of the 110 patients in the cohort, 59.1% were male and 90.9% were White. The median patient
age was 64 years. A total of 59 (53.6%) patients underwent resection; 37 of these demonstrated R0. The
30-day mortality rate was 5.1%; the complication rate was 39.0%. The rate of resectability increased over
time (36.4% vs. 70.9%; P = 0.001), as did the percentage of R0 resections (10.9% vs. 56.5%; P < 0.001).
Of the 59 patients who underwent resection, 23 (39.0%) experienced recurrence. Multivariable Cox
regression analysis identified resection margins [hazard ratio (HR) = 4.124 for positive vs. negative; P =
0.002] and type of operation (HR = 5.075 for exploration vs. resection; P = 0.001) as significant to survival.
Conclusions: Although R0 resection can be achieved in only a minority of patients, these patients have
a reasonable chance of longterm survival. The last decade has seen a significant rise in rates of
resectability of Klatskin's tumour at specialty centres.
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Introduction
Early experiences with hilar cholangiocarcinoma, or Klatskin’s
tumour, were often discouraging.1–5 However, despite poor overall
outcomes in these series, there was sporadic evidence of longterm
survival in patients in whom resection with negative margins (R0)
could be achieved. The lack of effective chemotherapy or radio-
therapy left surgical resection to represent the sole chance of long-
term survival.5–10 Inadequate understanding of hepatobiliary
drainage led to local biliary resections of hilar cholangiocarci-
noma that were plagued by multiple local tumour recurrences.
This overly common outcome led to a nihilistic view of hilar
cholangiocarcinoma.9 In the late 1990s, select Japanese and
American centres began to advocate a more aggressive approach
to hilar cholangiocarcinoma involving a radical biliary resection
with a segmental hepatic resection inclusive of segment I.11–15 This
approach resulted in dramatic improvements in survival and
decreases in local tumour recurrence. To date, several centres have
reported their experiences in hilar cholangiocarcinoma.16–34
Renewed interest in the management of hilar cholangiocarcinoma
combined with modern interventional radiology techniques
makes this a timely study. Improvements in endoscopic and per-
cutaneous biliary drainage, as well as portal vein embolization
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(PVE) for inadequate remnant liver after resection, have improved
the armamentarium for successful resection of these tumours.34–37
Here, we report our experience with 110 consecutive patients who
underwent surgical exploration for hilar cholangiocarcinoma
(Klatskin’s tumour).
Materials and methods
From January 1992 to December 2010, 110 consecutive patients
with hilar cholangiocarcinoma underwent surgical exploration at
the University of Louisville or the University of Cincinnati. All
data were collected through an institutional review board (IRB)-
approved protocol at both institutions. Data were then analysed in
a retrospective fashion. This analysis included patient demo-
graphics, and clinical, laboratory and radiologic evaluations,
which were correlated with pathologic specimens and patient
outcomes.
An initial assessment of these patients included laboratory
testing and cross-sectional imaging, usually with triple-phase
computed tomography (CT). Initial drainage and cytologic evalu-
ations were performed through endoscopic retrograde cholang-
iography (ERCP) or percutaneous transhepatic cholangiography
(PTC) with brushings. A recent addition to our patient evaluation
process has been cholangioscopy. After diagnostic imaging, an
aggressive approach to percutaneous drainage and PVE, where
indicated to improve resection remnant, was adopted. During the
placement of percutaneous transhepatic catheters, percutaneous
liver biopsy was performed to elucidate the presence of cirrhosis.
To adequately address hyperbilirubinaemia, a three-system
method of drainage was advocated, in which a single catheter was
placed in the left biliary radical and dual drainage was applied to
the right anterior and right posterior biliary systems. Triple-phase
CT imaging was used to evaluate potential post-resection remnant
size and to assess the extent and potential resectability of the
lesion. Magnetic resonance imaging (MRI) was used in selected
cases; however, MRI was generally applied according to institu-
tional experience and preference, and its use was rare overall. A
remnant size of <1000 ml was generally considered as an indica-
tion to proceed with PVE. Portal vein embolization was carried
out with a sealant material to avoid the use of coils. Coils were
avoided to prevent stapler misfiring during resection. The extent
of embolization was based on the collateral blood flow through
segment IV. Complete embolization of segment IV is felt to
improve the percentage of patients who demonstrate post-
embolization growth. After embolization, patients were reimaged
within 4–6 weeks. If future liver remnant hypertrophy was inad-
equate, patients were reimaged after an additional 2 weeks. With
the exception of the recent addition of cholangioscopy, the pre-
operative workup procedure remained largely consistent through-
out the study period. Preoperative criteria for unresectability have
been previously described by Jarnagin et al.29 and in general are
related to unfitness for a major operation, extensive bilateral
hepatic involvement and disseminated disease.
The final determination of resectability was made intraopera-
tively to exclude peritoneal or distant metastases not identified on
preoperative imaging. Criteria for unresectability during explora-
tion were: (i) peritoneal disease; (ii) bilateral liver involvement;
(iii) inadequate hepatic reserve; (iv) main hepatic artery encase-
ment with tumour, and (v) inadequate length of portal vein for
vascular reconstruction. Intraoperative ultrasound (IOUS) is a
critical component of intraoperative assessment, particularly in
identifying intrahepatic metastases or advanced bilateral biliary
involvement not identified on preoperative imaging.
Resection proceeded with mobilization of the hepatic bifurca-
tion and division of the vasculature to the specimen side. In cases
of vascular resection, primary anastamosis of redundant vascula-
ture was preferred to the use of an inter-position graft. Lobar
resection including removal of the caudate lobe was preferentially
carried out concomitantly with local tumour resection. Margins
from the hepatic substance and each of the biliary radicals were
sent for intraoperative frozen section. R0 resection was defined as
the provision of a final permanent section free of microscopic
tumour. R1 resection was defined as the leaving of microscopically
positive margins, and R2 resection was defined as the leaving of
gross residual disease.
Outcomes for the first 55 patients (first-era group) and the
most recent 55 patients (second-era group), respectively, were
analysed and compared. Continuous and categorical variables
were analysed using the Wilcoxon rank sum test and Fisher’s exact
test, respectively. Multivariable logistic regression was utilized to
determine factors related to resectability and margin status. Sur-
vival was calculated using the Kaplan–Meier method and com-
pared between groups using the log-rank test. Length of survival
was calculated as the period from the date of initial operation to
the date of death or last follow-up. Cox regression analysis was
used to evaluate for independent predictors of outcome using
survival as the dependent variable and factors found to be signifi-
cant on univariate analysis as covariates. A significance level of P <
0.05 was set. All statistical analysis was performed using sas
Version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient presentation
Of the 110 consecutive patients evaluated for hilar cholangiocar-
cinoma, the majority were White males. Their median age was 64
years. The most common presenting symptoms were jaundice,
weight loss and abdominal pain (Table 1). Biopsy in seven patients
showed fibrotic or cirrhotic disease. Median laboratory values at
presentation were: bilirubin, 6.0 mg/dl; alkaline phosphatase
(ALP), 475 IU/l, and carbohydrate antigen 19-9 (CA19-9), 257.5.
Diagnostic imaging and preoperative staging
Of the 106 patients in whom preoperative brushings were per-
formed, cytology was positive in 39 (36.8%). Five of the most
recent 55 patients were deemed marginal candidates based on
their marginal residual liver remnant and underwent PVE
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(Table 1). Computed tomography scanning was performed in 109
patients and MRI was performed in 10. Percutaneous transhepatic
cholangiography catheters were placed in 55 patients.
Operative morbidity and mortality
A total of 110 patients were explored for potential resection. Intra-
operative findings precluded surgical resection in 51 patients. The
remaining 59 (53.6%) patients underwent attempted curative
resection. In the patients who underwent resection, R0 margins
were achieved in 37 and R1 margins were obtained in the remain-
ing 22. There were no R2 resections in this series. Lobar resection
was performed in 49 (83.1%) of the resected patients. Overall
morbidity and 30-day mortality in the resected patients were
39.0% and 5.1%, respectively.
Resection and operative margins
Univariate analysis revealed era (first vs. second), the use of PTC,
positive brushings, node status and perineural invasion to be sig-
nificantly associated with resectability (Table 2). There was a trend
towards a higher resection rate in patients undergoing preopera-
tive PVE (P = 0.060). Multivariate analysis revealed only nodal
invasion to be an independent predictor of resectability [odds
ratio (OR) = 0.010, 95% confidence interval (CI) < 0.001–0.226;
P = 0.004]. In patients who underwent resection, CA19-9 levels,
era, lobar resection, perineural invasion and lymphatic invasion
were significantly associated with the achievement of negative
margins (Table 3). Multivariate analysis revealed only era of
resection (first vs. second) to be an independent predictor of R0
resection (OR = 0.016, 95% CI < 0.001–0.462; P = 0.016).
Survival
Rates of 1-, 3- and 5-year survival in the first 55 patients were
25.5%, 10.9% and 7.3%, respectively. In the most recent 55
patients, 1-, 3- and 5-year survival significantly increased to
56.3%, 36.5% and 33.7%, respectively (P = 0.001) (Table 4).
Table 1 Patient characteristics and comparison by era
All patients (n = 110) Era 1 patients (n = 55) Era 2 patients (n = 55) P-value
Age, years, median (range) 64 (21–88) 62 (21–88) 66 (27–88) 0.072
Sex, n (%)
Male 65 (59.1%) 32 (58.2%) 33 (60.0%)
Female 45 (40.9%) 23 (41.8%) 22 (40.0%) 1.00
Race, n (%)
White 100 (90.9%) 51 (92.7%) 49 (89.1%)
African-American 8 (7.3%) 3 (5.5%) 5 (9.1%)
Asian 1 (0.9%) 1 (1.8%) 0
Hispanic 1 (0.9%) 0 1 (1.8%) 0.601
Weight loss, n (%) 57 (51.8%) 27 (49.1%) 30 (54.6%) 0.703
Pain, n (%) 24 (21.8%) 13 (23.6%) 11 (20.0%) 0.818
Jaundice, n (%) 91 (82.7%) 46 (83.6%) 45 (81.8%) 1.00
CT mass, n (%) 48 (46.6%) 28 (50.9%) 20 (41.7%) 0.423
Cirrhosis, n (%) 7 (6.4%) 2 (3.6%) 5 (9.1%) 0.438
PSC, n (%) 9 (8.2%) 2 (3.6%) 7 (12.7%) 0.161
Bilirubin, mg/dl, median (range) 6.0 (0.2–35.1) 4.1 (0.4–35.1) 8.3 (0.2–35.0) 0.080
ALP, IU/l, median (range) 475.0 (1–3 037) 544.0 (103–3 037) 425.0 (1–1 244) 0.086
CA19-9, median (range) 257.5 (5–45 000) 280.0 (5–45 000) 212.5 (15–30 484) 0.562
Positive brushings, n (%) 39 (36.8%) 14 (25.5%) 25 (49.0%) 0.016
PTC, n (%) 55 (50.0%) 18 (32.7%) 37 (62.3%) 0.001
PVE, n (%) 5 (4.6%) 0 5 (9.1%) 0.057
Lymph node invasion, n (%) 59 (53.6%) 39 (70.9%) 20 (36.4%) 0.001
Perineural invasion, n (%) 59 (60.2%) 39 (70.9%) 20 (46.5%) 0.022
Type of surgery, n (%)
Resection 59 (53.7%) 20 (36.4%) 39 (70.9%)
Exploration 51 (46.4%) 35 (63.6%) 16 (29.1%) 0.001
Lobar resection, n (%) 49 (44.5%) 15 (27.3%) 34 (61.8%) <0.001
R0 resection, n (%) 37 (33.6%) 6 (10.9%) 31 (56.5%) <0.001
CT, computed tomography; PSC, primary sclerosing cholangitis; ALP, alkaline phosphatase; PTC, percutaneous transhepatic cholangiography; PVE,
portal vein embolization.
P-values refer to the comparison between Era 1 and Era 2. Values in bold are significant at <0.05.
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Patients who underwent resection had significantly higher median
survival (22.5 months vs. 4.0 months; P < 0.001) than those who
did not (Fig. 1). The ability to achieve negative margins increased
median survival from 4.4 months to 88.2 months (P < 0.001)
(Fig. 2). Resection to positive (R1) margins significantly increased
median survival over exploration alone (16.3 months vs. 4.0
months; P < 0.001) (Fig. 3). Perineural invasion (median survival:
4.3 months vs. 23.5 months; P < 0.001) and positive lymph nodes
(median survival: 4.0 months vs. 32.4 months; P < 0.001) were
associated with significantly decreased survival. Multivariate
analysis of the variables significant on univariate analysis revealed
margin status and resection vs. exploration to be independent
predictors of survival (Table 5).
Discussion
Historically, hilar cholangiocarcinoma has been considered
as a uniformly lethal disease in which expectations for 5-year
survival are low. However, as our ability to safely perform
hepatic resection has improved, so has the outlook for selected
patients with hilar cholangiocarcinoma. Hepatic resection has
now become a widely accepted component of surgical therapy
and its increased adoption is likely to represent the major
driver for the improved rates of resectability seen in this current
series.
Our current analysis demonstrated that a survival advantage is
associated with resection (vs. no resection) and negative margin
status. Our data also show the superiority of resection with R1
margins to exploration alone in terms of survival. Multiple studies
have confirmed the value of surgical resection. In this setting,
5-year survival after resection of hilar cholangiocarcinoma has
been reported to range from 4% to 37%.10–15, 17–25 Recognition of
the importance of concomitant hepatic resection is probably a key
factor in the improved rates of resectability apparent in the more
recent era of this current series. Lobar resection was performed in
only 27.3% of surgically evaluated patients in the first era of this
Table 2 Univariate analysis of factors affecting resection
Resection group (n = 59) Exploration group (n = 51) P-value
Age, years, median (range) 66 (21–88) 62 (32–82) 0.259
Bilirubin, mg/dl, median (range) 8.2 (0.2–35.0) 4.0 (0.4–35.1) 0.235
ALP, IU/l, median (range) 418 (96–3 037) 544 (1–2 750) 0.140
CA19-9, median (range) 214 (5–45 000) 305 (11–30 484) 0.295
Sex, n (%)
Male 34 (52.3%) 31 (47.7%)
Female 25 (55.6%) 20 (44.4%) 0.693
Race, n (%)
White 54 (54.0%) 46 (46.0%)
African-American 5 (62.5%) 3 (37.5%)
Asian 0 1 (100.0%)
Hispanic 0 1 (100.0%) 0.524
Pain, n (%) 11 (45.8%) 13 (54.2%) 0.489
Weight loss, n (%) 33 (57.9%) 24 (42.1%) 0.444
Jaundice, n (%) 49 (53.9%) 42 (46.2%) 1.00
CT mass, n (%) 24 (50.0%) 24 (50.0%) 0.557
Era, n (%)
First era 20 (36.4%) 35 (63.6%)
Second era 39 (70.9%) 16 (29.1%) 0.001
PTC, n (%) 37 (67.3%) 18 (32.7%) 0.007
PVE, n (%) 5 (100.0%) 0 0.060
PSC, n (%) 5 (55.6%) 4 (44.4%) 1.00
Cirrhosis, n (%) 5 (71.4%) 2 (28.5%) 0.447
Nodal invasion, n (%) 9 (15.3%) 50 (84.8%) <0.001
Brushings positive, n (%) 26 (66.7%) 13 (33.3%) 0.047
Perineural invasion, n (%) 11 (18.6%) 48 (81.4%) <0.001
ALP, alkaline phosphatase; CT, computed tomography; PSC, primary sclerosing cholangitis; PTC, percutaneous transhepatic cholangiography; PVE,
portal vein embolization.
P-values refer to the difference between the resection and exploration groups. Values in bold are significant at <0.05.
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study. In the second era, lobar resection was performed in 61.8%
of patients. Ability and willingness to extend the field of resection
to include concurrent hepatic lobectomy are probably the major
reasons why resectability in this series increased from 36.4% in the
first-era group to 70.9% in the second-era group.
Despite current acceptance that combined biliary hepatic resec-
tion provides improved survival over isolated ductal resection,
several controversies remain. These refer to the concept of inad-
equate residual hepatic reserve, and the extent of resection
required to provide negative margins. The most controversial
issue has concerned the extent of resection required to obtain
tumour-free surgical margins. Several authors have described
portal vein resection with reconstruction.38–41 Hemming et al.38
and Neuhaus et al.22 appear to be the most vocal advocates for
portal vein resection. En bloc vascular resection avoids the dissec-
tion of tumour-bearing planes, which gives this technique a theo-
retical advantage. Our group has also selectively utilized the
technique of portal vein resection to achieve negative margins.
Several groups have demonstrated success using these techniques
without an increase in associated morbidity or mortality.38–40
Table 3 Univariate analysis of factors affecting the ability to achieve margin-negative resection
R1 R0 P-value
Age, years, median (range) 63 (21–88) 64 (27–88) 0.435
Bilirubin, mg/dl, median (range) 5.7 (0.4–35.1) 7.4 (0.2–30.0) 0.483
ALP, IU/l, median (range) 530 (1–3 037) 418 (96–745) 0.105
CA19-9, median (range) 397.5 (11–45 000) 128.2 (5–2 459) 0.023
Sex, n (%)
Male 14 (41.2%) 20 (58.8%)
Female 8 (32.0%) 17 (68.0%) 0.589
Race, n (%)
White 22 (40.7%) 32 (59.3%)
African-American 0 5 (100.0%) 0.146
Pain, n (%) 2 (18.2%) 9 (81.8%) 0.184
Weight loss, n (%) 11 (33.3%) 22 (66.7%) 0.590
Jaundice, n (%) 19 (38.8%) 30 (61.2%) 0.729
CT mass, n (%) 8 (33.3%) 16 (66.7%) 0.584
Brushings positive, n (%) 9 (64.6%) 17 (65.4%) 0.598
Era, n (%)
First era 14 (70.0%) 6 (30.0%)
Second era 8 (20.5%) 31 (79.5%) <0.001
PTC, n (%) 14 (37.8%) 23 (62.2%) 1.00
PVE, n (%) 0 5 (100.0%) 0.146
PSC, n (%) 2 (40.0%) 3 (60.0) 1.00
Cirrhosis, n (%) 2 (40.0%) 3 (60.0%) 1.00
Nodal invasion, n (%) 7 (77.8%) 2 (22.2%) 0.010
Perineural invasion, n (%) 8 (72.7%) 3 (27.3%) 0.040
Lobar resection, n (%) 14 (29.2%) 34 (70.8%) 0.013
ALP, alkaline phosphatase; CT, computed tomography; PSC, primary sclerosing cholangitis; PTC, percutaneous transhepatic cholangiography; PVE,
portal vein embolization.
P-values refer to comparison between patients with R1 and R0 resection. Values in bold are significant at <0.05.
Table 4 Survival rates over 1, 3 and 5 years and median survival
Survival P-value
1-year 3-year 5-year Median, months
All patients 41.7% 23.1% 17.7% 8.0
First-era group 25.5% 10.9% 7.3% 5.4
Second-era group 56.3% 36.5% 33.7% 18.8 0.001
P-values refer to the comparison between Era 1 and Era 2 and are significant at <0.05.
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Significant emphasis has been placed on the risk for liver failure
associated with an inadequate liver remnant post-resection. This
becomes even more significant when the cholangiocarcinoma is
associated with primary sclerosing cholangitis with fibrosis or
cirrhosis. To avoid inadequate reserve and the risk of liver insuf-
ficiency, our group advocates ensuring a calculated remnant based
on a preoperative triphasic CT scan and a preoperative liver
biopsy to evaluate the hepatic substance for any evidence of fibro-
sis or cirrhosis. Our current threshold for the consideration of
PVE is a predicted future liver remnant of <1000 ml. This figure is
based on the transplant experience of the senior author, which
implies that 1000 ml is considered to represent the minimal graft
volume able to provide sufficient hepatic function. However, this
number is only a rough approximation and the decision on what
constitutes adequate hepatic parenchyma must be tailored to each
patient based on his or her level of hepatic functioning. We also
advocate the use of sealant glues over coil embolization in
response to concerns over stapler misfire. Imperative to adequate
embolization is the understanding of segment IV collateral flow,
and the need for selective embolization of this segment to provide
adequate contralateral growth. An adequate period of observa-
tion, generally of 4–6 weeks, is also required to allow the fullest
extent of hepatic hypertrophy.34–36 The adoption of PVE is likely to
represent another important reason for the improved rate of
resectability seen in the second-era patient group in this series.
Five patients in the second-era group underwent PVE and four of
them went on to receive bile duct excision with concurrent lobec-
tomy and hepaticojejunostomy. In the first era of our study
period, these patients would not have been deemed surgical can-
didates based on inadequate future liver remnant. In the future,
PVE is certain to play an increasingly important role in the pre-
operative preparation of patients with Klatskin’s tumour.
The final controversy refers to preoperative biliary instrumen-
tation. Several studies have cautioned that the use of preoperative
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Figure 1 Comparison of survival in patients undergoing surgery with
curative intent (resection performed) ( ) vs. those undergoing
exploration alone ( ), showing product-limit survival estimates and
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Figure 2 Comparison of survival in patients undergoing margin-
negative resection ( ) vs. margin-positive resection or exploration
alone ( ), showing product-limit survival estimates and number of





























5 3 3 3
30 40 50 60
TYPESURG 1 : R1 2 : Exploration
Figure 3 Comparison of survival in patients undergoing R1 resection
( ) vs. those undergoing exploration alone ( ), showing product-
limit survival estimates and number of subjects at risk (log-rank test,
P < 0.0001)
Table 5 Multivariate Cox proportional hazards analysis of survival
HR 95% CI P-value
Era (first vs. second) 0.971 0.592–1.592 0.907
Exploration vs. resection 5.075 1.965–13.106 0.001
Residual disease after operation 4.124 1.706–9.968 0.002
Nodal invasion 1.353 0.215–8.504 0.747
Perineural invasion 1.036 0.179–5.985 0.969
HR, hazard ratio; 95% CI, 95% confidence interval.
P-values in bold are significant at <0.05.
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postoperative infection, whereas other reports have indicated
improvement in the post-resection liver remnant.33,37,41,42 Our
group advocates the drainage of all three sectors of the liver to
decrease serum bilirubin to <10 mg/dl to improve the function of
the remnant liver. Early in the series, it was our policy to continue
biliary drainage for 6–8 weeks. In more recent patients, we have
limited the period of drainage to 1–2 weeks preoperatively. In
regard to a technical aspect, stenting also provides a clear plane for
dissection and leads to localized fibrosis in the stented biliary
radicle. In the present series, stenting represents another factor
contributing to the higher resection rates achieved in the second-
era patient group. Furthermore, fibrosis of the duct provides
better purchase for a subsequent biliary enteric anastamosis.
Renewed attempts at liver transplantation in hilar cholangio-
carcinoma have been met with newfound enthusiasm.43–45 All
transplantation protocols are based on either pretransplant
chemoradiation therapy or chemophotodynamic therapy. Unfor-
tunately, although numerous patients are screened, only a minor-
ity are actually eligible for transplantation. Despite the role of
chemotherapy in the neoadjuvant protocol for transplantation, no
solid clinical evidence exists for the postoperative administration
of chemotherapy in patients undergoing resection for hilar cho-
langiocarcinoma. Some series have demonstrated modest
improvements in survival,46,47 but this benefit has never been dem-
onstrated clearly in a large prospective trial.
Conclusions
Over the last two decades, the treatment of hilar cholangiocarci-
noma has continued to rest firmly on the same cornerstone: re-
section to negative margins of the biliary tree and hepatic paren-
chyma. Clear benefit has been observed with the use of an aggres-
sive approach to surgical resection, including concomitant
hepatectomy. More uncertain is the use of portal vein resec-
tion or pancreatoduodenectomy to achieve tumour-free margins.
Advances in interventional radiology, and in percutaneous tran-
shepatic biliary drainage, PVE, anaesthesia and critical care tech-
niques have made the achievement of a higher percentage of R0
resections feasible. However, even when negative margins cannot
be achieved, there is still a survival benefit to patients who undergo
surgical resection of all gross disease. Despite the renewed hope
that other modalities such as transplantation and adjuvant chemo-
radiotherapy or chemophotodynamic therapy will prove feasible,
aggressive resection remains the principal treatment for hilar cho-
langiocarcinoma. The major limitations of this study refer to its
retrospective nature and the fact that it was confined to patients
who had been referred for surgical evaluation. The number of
patients who are not referred for surgery is substantial and prob-
ably constitutes the majority of patients with hilar cholangiocar-
cinoma. Including these patients would provide a better estimate
of the true resectability rate. Furthermore, it is possible that
changes in referral patterns may play a role in the increased rate of




1. Klatskin G. (1965) Adenocarcinoma of the hepatic duct at its bifurcation
within the porta hepatis. An unusual tumour with distinctive clinical and
pathological features. Am J Med 38:241–256.
2. Altemeier WA, Gall EA, Zinninger MM, Hoxworth PI. (1957) Sclerosing
carcinoma of the major intrahepatic bile ducts. AMA Arch Surg 75:450–
460.
3. Longmire WP, McArthur MS, Bastounis EA, Hiatt J. (1973) Carcinoma of
the extrahepatic biliary tract. Ann Surg 178:333–345.
4. Launois B, Campion JP, Brissot P, Gosselin M. (1979) Carcinoma of the
hepatic hilus. Surgical management and the case for resection. Ann Surg
190:151–157.
5. Fortner JG, Kallum BO, Kim DK. (1976) Surgical management of carci-
noma of the junction of the main hepatic ducts. Ann Surg 184:68–73.
6. Jarnagin WR, Shoup M. (2004) Surgical management of cholangiocarci-
noma. Semin Liver Dis 24:189–199.
7. Forsmo HM, Horn A, Viste A, Hoem D, Ovrebo K. (2008) Survival and an
overview of decision-making in patients with cholangiocarcinoma. Hepa-
tobiliary Pancreat Dis Int 7:412–417.
8. Tompkins RK, Thomas D, Wile A, Longmire WP Jr. (1981) Prognostic
factors in bile duct carcinoma: analysis of 96 cases. Ann Surg 194:447–
457.
9. Lai EC, Tompkins RK, Mann LL, Roslyn JJ. (1987) Proximal bile duct
cancer. Quality of survival. Ann Surg 205:111–118.
10. Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM
et al. (2008) Aggressive surgical resection for hilar cholangiocarcinoma: is
it justified? Audit of a single centre's experience. Am J Surg 196:160–169.
11. Nishio H, Nagino M, Nimura Y. (2005) Surgical management of hilar
cholangiocarcinoma: the Nagoya experience. HPB (Oxford) 7:259–262.
12. Ito F, Agni R, Rettammel RJ, Been MJ, Cho CS, Mahvi DM et al. (2008)
Resection of hilar cholangiocarcinoma: concomitant liver resection
decreases hepatic recurrence. Ann Surg 248:273–279.
13. Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T et al.
(2004) Forty consecutive resections of hilar cholangiocarcinoma with no
postoperative mortality and no positive ductal margins: results of a pro-
spective study. Ann Surg 240:95–101.
14. Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y et al.
(1998) Aggressive surgical approaches to hilar cholangiocarcinoma:
hepatic or local resection? Surgery 123:131–136.
15. Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M et al.
(2000) Management of hilar cholangiocarcinoma: comparison of an
American and a Japanese experience. Ann Surg 232:166–174.
16. Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I et al.
(1998) Treatment of hilar cholangiocarcinoma (Klatskin tumours) with
hepatic resection or transplantation. J Am Coll Surg 187:358–364.
17. Hidalgo E, Asthana S, Nishio H, Wyatt J, Toogood GJ, Prasad KR et al.
(2008) Surgery for hilar cholangiocarcinoma: the Leeds experience. Eur J
Surg Oncol 34:787–794.
18. Mansfield SD, Barakat O, Charnley RM, Jaques BC, O'Suilleabhain CB,
Atherton PJ et al. (2005) Management of hilar cholangiocarcinoma in the
north of England: pathology, treatment, and outcome. World J Gastro-
enterol 11:7625–7630.
19. Launois B, Terblanche J, Lakehal M, Catheline JM, Bardaxoglou E,
Landen S et al. (1999) Proximal bile duct cancer: high resectability rate
and 5-year survival. Ann Surg 230:266–275.
148 HPB
HPB 2012, 14, 142–149 © 2011 International Hepato-Pancreato-Biliary Association
20. Gerhards MF, van Gulik TM, Bosma A, ten Hoopen-Neumann H,
Verbeek PC, Gonzalez GD et al. (1999) Longterm survival after resection
of proximal bile duct carcinoma (Klatskin tumours). World J Surg 23:91–
96.
21. Capussotti L, Muratore A, Polastri R, Ferrero A, Massucco P. (2002) Liver
resection for hilar cholangiocarcinoma: in-hospital mortality and longterm
survival. J Am Coll Surg 195:641–647.
22. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N et al.
(1999) Extended resections for hilar cholangiocarcinoma. Ann Surg
230:808–818.
23. Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. (2005)
Surgery for hilar cholangiocarcinoma: a 10-year experience of a tertiary
referral centre in the UK. Eur J Surg Oncol 31:533–539.
24. Baton O, Azoulay D, Adam DV, Castaing D. (2007) Major hepatectomy for
hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm
outcomes. J Am Coll Surg 204:250–260.
25. Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, van Gulik TM.
(2006) Improved outcome of resection of hilar cholangiocarcinoma
(Klatskin tumour). Ann Surg Oncol 13:872–880.
26. Olnes MJ, Erlich R. (2004) A review and update on cholangiocarcinoma.
Oncology 66:167–179.
27. Blechacz BR, Gores GJ. (2008) Cholangiocarcinoma. Clin Liver Dis
12:131–150.
28. Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. (2005)
Surgical management of hilar cholangiocarcinoma. Ann Surg 241:693–
699.
29. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ
et al. (2001) Staging, resectability, and outcome in 225 patients with hilar
cholangiocarcinoma. Ann Surg 234:507–517.
30. Ikeyama T, Nagino M, Oda K, Ebata T, Nishio H, Nimura Y. (2007)
Surgical approach to Bismuth Type I and II hilar cholangiocarcinomas:
audit of 54 consecutive cases. Ann Surg 246:1052–1057.
31. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. (1999)
Improved surgical results for hilar cholangiocarcinoma with procedures
including major hepatic resection. Ann Surg 230:663–671.
32. Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart
B et al. (2004) Major hepatic resection for hilar cholangiocarcinoma:
analysis of 46 patients. Arch Surg 139:514–523.
33. Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T et al.
(2003) Longterm outcome of extended hemihepatectomy for hilar
bile duct cancer with no mortality and high survival rate. Ann Surg
238:73–83.
34. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG
et al. (2003) Preoperative portal vein embolization for extended hepate-
ctomy. Ann Surg 237:686–691.
35. Yokoyama Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. (2007)
Recent advances in the treatment of hilar cholangiocarcinoma: portal
vein embolization. J Hepatobiliary Pancreat Surg 14:447–454.
36. Palavecino M, Abdalla EK, Madoff DC, Vauthey JN. (2009) Portal vein
embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am 18:257–
267.
37. Nimura Y. (2008) Preoperative biliary drainage before resection for cho-
langiocarcinoma (Pro). HPB (Oxford) 10:130–133.
38. Hemming AW, Kim RD, Mekeel KL, Fujita S, Reed AI, Foley DP et al.
(2006) Portal vein resection for hilar cholangiocarcinoma. Am Surg
72:599–604.
39. Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M et al. (2007)
Combined vascular resection in operative resection for hilar cholangio-
carcinoma: does it work or not? Surgery 141:581–588.
40. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. (2003)
Hepatectomy with portal vein resection for hilar cholangiocarcinoma:
audit of 52 consecutive cases. Ann Surg 238:720–727.
41. Takada T. (2001) Is preoperative biliary drainage necessary according to
evidence-based medicine? J Hepatobiliary Pancreat Surg 8:58–64.
42. Hochwald SN, Burke EC, Jarnagin WR, Fong Y, Blumgart LH. (1999)
Association of preoperative biliary stenting with increased postoperative
infectious complications in proximal cholangiocarcinoma. Arch Surg
134:261–266.
43. Rosen CB, Heimbach JK, Gores GJ. (2010) Liver transplantation for
cholangiocarcinoma. Transpl Int 23:692–697.
44. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T
et al. (2002) Radiochemotherapy and transplantation allow longterm
survival for non-resectable hilar cholangiocarcinoma. Am J Transplant
2:774–779.
45. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani
MB et al. (2004) Liver transplantation for unresectable perihilar cholang-
iocarcinoma. Semin Liver Dis 24:201–207.
46. Hejna M, Pruckmayer M, Raderer M. (1998) The role of chemotherapy
and radiation in the management of biliary cancer: a review of the litera-
ture. Eur J Cancer 34:977–986.
47. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura
H et al. (2009) Gemcitabine-based adjuvant chemotherapy improves sur-
vival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest
Surg 13:1470–1479.
HPB 149
HPB 2012, 14, 142–149 © 2011 International Hepato-Pancreato-Biliary Association
